Laura Cove-Smith

525 total citations
23 papers, 268 citations indexed

About

Laura Cove-Smith is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Laura Cove-Smith has authored 23 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Laura Cove-Smith's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (4 papers). Laura Cove-Smith is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (4 papers). Laura Cove-Smith collaborates with scholars based in United Kingdom, Italy and Spain. Laura Cove-Smith's co-authors include Kim Linton, John Radford, Jonathan Tugwood, Howard R. Mellor, Hana Alachkar, Rebecca Brooke, Corinne Faivre‐Finn, Matthias Schmitt, Maria Rita Migliorino and Marina Chiara Garassino and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and British Journal of Pharmacology.

In The Last Decade

Laura Cove-Smith

20 papers receiving 265 citations

Peers

Laura Cove-Smith

ONCOL

PRM

CCM

RNMI

J. Marruecos Spain

Muneeb Rehman United States

Chen Zhu China

Maria Mitry United States

Zhonghang Xu China

Włodzimierz Kupis Poland

Paola Venturino Italy

Xulong Sun China

Anchit Bhagat United States

J. Marruecos Spain

Laura Cove-Smith

98 ×0.8

ONCOL

135 ×1.5

PRM

13 ×0.2

CCM

63 ×1.4

38 ×1.1

RNMI

Citations per year, relative to Laura Cove-Smith Laura Cove-Smith (= 1×) peers J. Marruecos

Countries citing papers authored by Laura Cove-Smith

Since Specialization

Citations

This map shows the geographic impact of Laura Cove-Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Cove-Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Cove-Smith more than expected).

Fields of papers citing papers by Laura Cove-Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Cove-Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Cove-Smith. The network helps show where Laura Cove-Smith may publish in the future.

Co-authorship network of co-authors of Laura Cove-Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Cove-Smith. A scholar is included among the top collaborators of Laura Cove-Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Cove-Smith. Laura Cove-Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Longo, Vito, Domenico Galetta, Sara Pilotto, et al.. (2025). Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy. European Journal of Cancer. 221. 115435–115435. 2 indexed citations

Garassino, Marina Chiara, Jonathan Khalifa, Martin Reck, et al.. (2025). Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial. ESMO Open. 10(6). 105071–105071. 2 indexed citations

Evison, Matthew, Tasnim Ahmed, Meenali Chitnis, et al.. (2025). Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017–2025. Thorax. thorax–2025.

Kennedy, Oliver, Rebecca Lee, Safwaan Adam, et al.. (2024). Seasonal patterns in immunotherapy outcomes.. Journal of Clinical Oncology. 42(16_suppl). e14684–e14684. 1 indexed citations

Escriu, Carles, Riyaz Shah, Samantha Cox, et al.. (2024). Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis. Therapeutic Advances in Medical Oncology. 16. 12717693–12717693. 1 indexed citations

Garassino, M.C., Julien Mazières, Martin Reck, et al.. (2023). LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6. Annals of Oncology. 34. S1301–S1302. 3 indexed citations

Pearce, Mark S., Fábio Gomes, Colin R. Lindsay, et al.. (2023). 82P The role of circadian rhythms in NSCLC immunotherapy efficacy: A focus on first dose timing. Immuno-Oncology Technology. 20. 100554–100554. 1 indexed citations

Lewis, Jacob S., Helen Adderley, Matt Carter, et al.. (2023). Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 178. S34–S34.

Hodgson, Clare, Mathew Carter, Colin R. Lindsay, et al.. (2022). Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Targeted Oncology. 17(4). 453–465. 7 indexed citations

10.

Garassino, Marina Chiara, Julien Mazières, Martin Reck, et al.. (2022). Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. Journal of Thoracic Oncology. 17(12). 1415–1427. 69 indexed citations

11.

Balata, Haval, Julie Martin, Philip Crosbie, et al.. (2022). The diagnostic pathway in lung cancer patients with best supportive care decisions: are there lessons to be learnt?. Clinical Medicine. 22(3). 246–250. 3 indexed citations

12.

Garassino, M.C., Martin Reck, C. Chouaïd, et al.. (2022). 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Annals of Oncology. 33. S81–S82. 11 indexed citations

13.

Osborne, Lucy R., Clare Hodgson, Mark S. Pearce, et al.. (2022). Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 165. S46–S46. 1 indexed citations

14.

Tivey, Ann, et al.. (2020). Can frailty screening tools predict completion of chemotherapy and chemotherapy toxicity in patients with thoracic malignancy?. Journal of Geriatric Oncology. 11(7). 1154–1156. 4 indexed citations

15.

Gomes, Fábio, Katie Baker, Laura Cove-Smith, et al.. (2019). MA19.09 Assessing Clinical Frailty in Advanced Lung Cancer Patients - An Opportunity to Improve Patient Outcomes?. Journal of Thoracic Oncology. 14(10). S329–S329. 3 indexed citations

16.

Cove-Smith, Laura, et al.. (2018). Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Reports. 4(3). 229–231. 38 indexed citations

17.

Syed, Jamil, Fiona Blackhall, Laura Cove-Smith, et al.. (2018). Single institution analysis of pneumocystis jirovecii pneumonia in patients undergoing treatment for lung cancer: recommendations for PJP prophylaxis. Lung Cancer. 115. S9–S10. 1 indexed citations

18.

Cove-Smith, Laura, et al.. (2014). High-dose Interleukin 2-induced Myocarditis. Journal of Immunotherapy. 37(5). 304–308. 8 indexed citations

19.

Cove-Smith, Laura, Neil Woodhouse, Adam Hargreaves, et al.. (2014). An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. Toxicological Sciences. 140(1). 3–15. 50 indexed citations

20.

Cross, Michael, Brian R. Berridge, Peter Clements, et al.. (2014). Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury. British Journal of Pharmacology. 172(4). 957–974. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact